'Boomeranging' Back Home Hurts Young Adults' Mental Health

MAX PLANCK INSTITUTE FOR DEMOGRAPHIC | November 20, 2018

article image
The number of young adults living in their own household has dropped dramatically in the last decades in the United States for a number of economic and social reasons. In a study that will soon be published in the peer-reviewed journal Society and Mental Health, MPIDR researcher Jennifer Caputo investigated the effects of moving back home after a period of independence on young adults’ mental health. She found that young adults who “boomeranged” back to a parental home experienced an increase in depressive symptoms.

Spotlight

Amman Pharmaceutical Industries

Amman Pharmaceutical Industries (API) is the first pharmaceutical company in the MENA region to pioneer the production of niche branded generics in the lines of Ophthalmology, Nasals, and Topical Dermatology. After many years of success, API is proud to be a leader in Jordan and the MENA region having expanded into additional therapy areas and production lines which provide more than 150 registered products. The company employs more than 250 employees serving patients in more than 30 countries across the Middle East & Africa & CIS regions.

OTHER ARTICLES

Tips for Managing Chronic Pain Beyond Prescription Painkillers

Article | February 17, 2020

Painkillers like Oxycontin, Percocet, and Vicodin, have been prescribed by primary physicians, surgeons, dentists, and other healthcare providers to patients suffering from varying levels of pain. Though these medications have proven to be an effective source of pain relief, they have also proven to be highly addictive. In fact, it has even been reported that there are more cases of a drug overdose and deaths from prescription painkillers than heroin or cocaine. While there are a number of factors that play into this opioid epidemic, educating doctors and patients on alternative solutions to managing chronic pain is a great place to start combatting this nationwide crisis.

Read More

Advance Your Pharma Supply Chain Planning during a Pandemic

Article | March 20, 2020

One predominant and common element within our pharmaceutical industry, is our devotions to patients. Within supply chain there is always a focus on ensuring the right product is delivered to the right place at the right time in order to ensure patient safety and the continuity of medicinal supplies. With the spread of COVID-19 across 117 countries and counting, every supply chain needs to evaluate their global footprint and develop contingency plans within their end to end operations.

Read More

Top Pharmaceutical Firms Urge FDA to Adopt Blockchain for Drug Tracking

Article | February 25, 2020

Leading market participants in the United States pharmaceutical industry, logistics firms, distributors and other stakeholders in the pharma supply chain have come together to publish a report buttressing the need for industry players to adopt blockchain for tracking prescription drugs, following the successful completion of a DLT pilot project with the Food and Drug Administration (FDA), according to reports on February 24, 2020. Though nascent, blockchain technology, the building blocks of Bitcoin (BTC) and other cryptocurrencies are fast gaining ground across various ecosystems, due to its immutability, security, privacy, and other intricate properties. In the latest development, 25 leading manufacturers of pharmaceutical products, logistics partners and other market participants in the pharma supply chain, have published a report that highlights the importance of blockchain technology in drug traceability.

Read More

Pricing of drugs – at what cost?

Article | February 27, 2020

We go into a doctor’s office and leave with a diagnosis and a prescription. Next we stop by the pharmacy. In Germany, if your insurance is not private, you mostly don’t even know the price of your drug because it’s paid for directly by your insurance. You only notice the 5-10 Euros copay. But how is a drug priced in Germany? And (how) does data play a role in helping pharma secure an attractive price point? Let’s fast forward directly to the launch of a new drug. At the time of launch, the pharmaceutical company has to present patient level evidence of the drug’s added value compared to existing comparative therapies. In the first year, however, the drug’s price can be defined freely by the company.

Read More

Spotlight

Amman Pharmaceutical Industries

Amman Pharmaceutical Industries (API) is the first pharmaceutical company in the MENA region to pioneer the production of niche branded generics in the lines of Ophthalmology, Nasals, and Topical Dermatology. After many years of success, API is proud to be a leader in Jordan and the MENA region having expanded into additional therapy areas and production lines which provide more than 150 registered products. The company employs more than 250 employees serving patients in more than 30 countries across the Middle East & Africa & CIS regions.

Events